Dorchester Minerals, L.P. Announces Its First Quarter Distribution DALLAS, April 24, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s first quarter 2025 cash distribution. The distribution of $0.725835 per common unit represents activity for the three-month period ended March 31, 2025 and is payable on May 15, 2025 to common unitholders of record as of May 5, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the first quarter totaled approximately $34.2 million. Approximately 68% of these receipts reflect oi...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development ...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore’s newly hi...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Th...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital Equipment, Raising Approximately $17.0 Million -- Conference Call Today at 4:30pm ET CHASKA, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025 Webcast Scheduled for Thursday, April 3 at 4:30 p.m. Eastern CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to disc...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Human...
Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows: TD Cowen 45th Annual Health Care ConferenceDetails: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will ...
Dorchester Minerals, L.P. Announces 2024 Results DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the year ended December 31, 2024 of $92,449,000 or $2.13 per common unit. A comparison of the Partnership’s consolidated results for the twelve month periods ended December 31, 2024 and 2023 are set forth below: Twelve Months Ended December 31, 2024 2023 Operating Revenues$161,523,000 $163,799,000 Net Income$92,449,000 $114,117,000 Net Income Per Common Unit$2.13 $2.85 The Partnersh...
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and ...
Dorchester Minerals, L.P. Announces Its Fourth Quarter Distribution DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- — Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s fourth quarter 2024 cash distribution. The distribution of $0.739412 per common unit represents activity for the three-month period ended December 31, 2024 and is payable on February 13, 2025 to common unitholders of record as of February 3, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the fourth quarter totaled approximately $34.9 million. Approximately 68% of these re...
Lifecore Biomedical Announces Special Stockholder Meeting Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it intends to hold a special meeting of its stockholders (the “Special Meeting”) on April 10, 2025 (the “Special Meeting Date”), to consider and vote on ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.